Nishant N. Vaikath - Concepedia

Author

Nishant N. Vaikath

Hamad bin Khalifa University ORCID

Also Known As

N. N. Vaikath, N. Vaikath, Nishant N Vaikath, Nishant N. Vaikath, Nishant Vaikath

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Hamad bin Khalifa University Qatar Foundation United Arab Emirates University Newcastle University Amsterdam Neuroscience

About

Nishant N. Vaikath is an author at Hamad bin Khalifa University specializing in neurodegenerative diseases, medicine, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	778
2	Natural Sciences	3	3	50
3	Social Sciences	3	3	374
4	Biochemistry	2	2	203
5	Biomolecular Engineering	1	1	16

Nishant N. Vaikath

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease Nour K. Majbour, Nishant N. Vaikath, Karin D. van Dijk, Molecular Neurodegeneration	2016	279
Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates Marie-Laure Arotçarena, Sandra Doveró, Alice Prigent, Brain	2020	201
Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration Megan F. Duffy, Timothy J. Collier, Joseph R. Patterson, Journal of Neuroinflammation	2018	196
α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity Simona S. Ghanem, Nour K. Majbour, Nishant N. Vaikath, Proceedings of the National Academy of Sciences Serine 129Molecular BiologySynaptic SignalingSocial Sciencesα-Synuclein Phosphorylation	2022	188
Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression Nour K. Majbour, Nishant N. Vaikath, Paolo Eusebi, Movement Disorders	2016	148
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology Nishant N. Vaikath, Nour K. Majbour, Katerina E. Paleologou, Neurobiology of Disease Neurodegenerative DiseasesImmunologyMolecular BiologyProtein MisfoldingAntibody Engineering	2015	138
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, The Lancet Neurology Neurodegenerative DiseasesAutoimmune DiseaseImmunologyNeurologyImmunotherapy	2020	132
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration Valentina Durante, Antonio de Iure, Vittorio Loffredo, Brain Synaptic TransmissionNeurochemical BiomarkersSynaptic SignalingSocial SciencesAlzheimer's Disease	2019	115
Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study Vincenzo Donadio, Alex Incensi, Omar M. A. El‐Agnaf, Scientific Reports	2018	100
α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies Inger van Steenoven, Nour K. Majbour, Nishant N. Vaikath, Movement Disorders	2018	100

Page 1